Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.80 |
| ▸ | ABL1 | P00519 | 8/20 | 0.60 |
| ▸ | BCR | P11274 | 8/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836061 | 0.95 | TRPV1 (0.87) | TRPV1ABL1BCRBACE1DYRK1A | |
| SCHEMBL1013650 | 0.89 | TRPV1 (1.00) | TRPV1ABL1BCRBACE1 | |
| SCHEMBL4832682 | 0.86 | TRPV1 (0.71) | TRPV1ABL1BCRBACE1 | |
| SCHEMBL1011712 | 0.77 | TRPV1 (1.00) | TRPV1ABL1BCRBACE1 | |
| SCHEMBL15534046 | 0.76 | ABL1 (0.68) | TRPV1ABL1BCRCLK4 | |
| SCHEMBL4832960 | 0.76 | ABL1 (0.72) | TRPV1ABL1BCRCLK4 | |
| SCHEMBL1016320 | 0.76 | ABL1 (0.76) | TRPV1ABL1BCRCLK4 | |
| SCHEMBL1013728 | 0.76 | ABL1 (0.76) | TRPV1ABL1BCRCLK4 | |
| SCHEMBL12943121 | 0.76 | ABL1 (1.00) | TRPV1ABL1BCRCLK4 | |
| SCHEMBL1012574 | 0.76 | ABL1 (0.75) | TRPV1ABL1BCRCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314933-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-01-01 | — | — | US | claimed |
| EP-1807418-A2 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT | Amgen, Inc (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006047492-A2 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT | AMGEN INC. (US) | 2006-05-04 | — | — | WO | claimed |
| US-20060089360-A1 | Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine | AMGEN INC. | 2006-04-27 | — | — | US | claimed |
| US-7314933-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314933-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089360-A1 | Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine | TRPV1, TRPA1, TRPV3 | TRPV1 1/4885ABL1 832/4885BCR 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.